Additional Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    Scottsdale AZ. 85259
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    Aurora CO. 80033
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    Houston TX. 77030
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    New Brunswick NJ. 08901
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    Cincinnati OH. 45206
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    Los Angeles CA. 90095
    View Details

  • A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

    GSK Investigational Site
    Baltimore MD. 21224
    View Details

  • Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease

    Institut Universitaire de Cardiologie et Pneumologie de Québec
    Quebec City QC.
    View Details

  • Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease

    Jewish General Hospital - CIUSSS-COMTL
    Montreal QC. H3T 1E2
    View Details

  • Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease

    Centre hospitalier de l'Université de Montréal (CHUM)
    Montreal QC. H2X 3E4
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    UCLA Health Westwood Medical Plaza
    Westwood CA. 90095
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Emory Clinic
    Atlanta GA. 30322
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Coastal Pulmonary and Critical Care PLC
    St. Petersburg FL. 33704-2733
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Banner University Medicine Lung Institute
    Phoenix AZ. 85006-2506
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    IntraCare Health Center ? Prestige
    Dallas TX. 75254
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    University of California, San Francisco-Fresno
    Fresno CA. 93701-2302
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    The University of Oklahoma Health Sciences Center
    Oklahoma City OK. 73104-5417
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    Pulmonix LLC
    Greensboro NC. 27403-4443
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    University of Southern California Keck School of Medicine
    Los Angeles CA. 90033-1036
    View Details

  • A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

    University of California, San Francisco Medical Center
    San Francisco CA. 94143-2204
    View Details